For those who didn't peruse the 10Q, a few highlig

For those who didn't peruse the 10Q, a few highlights from the 57 page pdf.

We sold 41K to Philippines(first order), the last order(or subsequent orders) were for an additional 200k (aka .2 million as described in the document). Any revenue is good revenue.

Still lots of debt and still had some cash as of the period ending for the document. Plenty of court filings to go around...and apparently the prostegene test is still an asset...who knew?

In the progress section pg. 28-29 HIV bla mentioned...exact wording
"In September 2021, the Company revised its current BLA resubmission completion date from October 2021 to the first calendar
quarter of 2022"

So there's the new timeline.

Kinda bummed that Nash wasn't mentioned in that list of the updates, but then again full trial data not known, but at least a mention of trial completion and forthcoming data would have been nice to see since they did have the recent Cancer trial contract signing listed.

Those were just a few things that stuck out to me, there is much more in there so definitely dig in when you have some free time...until tomorrows webcast anyway.